Anti-DP treatment after stem cell transplant to prevent relapse
Part of Blood & lymphatic clinical trials.
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (AML, ALL, CLL, or certain lymphoma types) and are planning an allogeneic stem cell transplant
- Your tissue type includes DPB1*04:01, and the donor is DPB1*04:01 negative (cord blood has specific matching rules too)
- Your transplant plan uses either donor stem cells from blood (PBSC) or bone marrow (PBSC donor must be able to use G-CSF to collect cells)
- You are 18 to 75 years old, and your cancer was in complete remission or shows enough response before transplant
- You are well enough for study treatment (ECOG 0–2 or Karnofsky score over 60%) and have adequate blood counts
- You must not be pregnant or breastfeeding, and you must agree to contraception if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
Hear when a new Haematologic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.